IL Dong Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
IL Dong Pharmaceutical makes prescription medicines, active-vitamin supplements (sold under the Aronamin brand), antibiotics, health supplements, and specialty nutritional foods for patients and consumers in South Korea.
Its products reach end users through the domestic healthcare and retail supply chain. Listed on KOSPI, South Korea's main stock exchange, the company's product range is anchored by its active-vitamin Aronamin line and the antibiotic Flumarin, which together represent its core manufactured goods.
Summary is AI-generated and may contain errors · figures from DART filings
IL Dong Pharmaceutical in five facts
What does IL Dong Pharmaceutical do?
IL Dong Pharmaceutical makes prescription medicines, active-vitamin supplements (sold under the Aronamin brand), antibiotics, health supplements, and specialty nutritional foods for patients and consumers in South Korea.
Where is IL Dong Pharmaceutical listed and in which sector?
IL Dong Pharmaceutical (Korean name: 일동제약) trades under KRX code 249420 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is IL Dong Pharmaceutical?
Its market capitalisation was US$320.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were IL Dong Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, IL Dong Pharmaceutical reported revenue of US$427.9M, operating profit of US$14.7M and net income of US$17.9M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was down 7.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Decision to acquire shares/equity in another company
IL Dong Pharmaceutical disclosed an acquisition, worth US$27.1M.
M&A · Sep 30 - Operating results (consolidated) (preliminary) (fair disclosure)
IL Dong Pharmaceutical filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$106M (+9% year on year), operating profit of US$3.52M (+739.1% year on year) and net income of US$5.72M (from a loss a year earlier).
Earnings · Jul 30 - Completion report on merger, etc. (merger)M&A · Jun 17
- Operating results (consolidated) (preliminary) (fair disclosure)
IL Dong Pharmaceutical filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$95.3M (+4.4% year on year), operating profit of US$6.19M (+120% year on year) and net income of US$4.95M (+1376.6% year on year).
Earnings · May 13 - [Attachment amended] Material event report (merger)M&A · Apr 15
- Material event report (merger)M&A · Apr 13
- Cash/in-kind dividend decision
IL Dong Pharmaceutical declared a cash dividend of US$0.14 per share.
Dividend · Feb 11 - Operating results (consolidated) (preliminary) (fair disclosure)
IL Dong Pharmaceutical filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$101M (−5.6% year on year), operating profit of US$5.45M (−5.7% year on year) and net income of US$3.87M (+97.1% year on year).
Earnings · Feb 11 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 27